EI
PHAS

EAM Investors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

EAM Investors’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-140,850
Closed -$1.85M – 323
2019
Q2 		$1.85M Buy
140,850
+46,468
+49% +$569K 0.45% 78
2019
Q1 		$898K Buy
+94,382
New +$374K 0.22% 196

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's PHAS Position: Q3 2019 in Review

EAM Investors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2019, closing a stake of 140,850 shares — an estimated $1.85M sold.

EAM Investors first reported a position in PHAS in Q1 2019 and held it in 2 quarters. The position peaked at $1.85M in Q2 2019. 58 funds tracked by Wall St. Rank hold PHAS as of Q3 2019.

  • EAM Investors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • EAM Investors sold 140,850 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $1.85M.
  • EAM Investors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • EAM Investors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.85M in Q2 2019.
  • 58 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on EAM Investors's 13F filing for Q3 2019, filed 13 Nov 2019.